Source comparison
Comparison: PT-141 vs PDE5 Inhibitors for Performance Anxiety
| Criterion | PT-141 (Bremelanotide) | Sildenafil (PDE5 Inhibitor) | Tadalafil (PDE5 Inhibitor) | Professional Assessment ||—|—|—|—|| Primary Mechanism | Central melanocortin receptor agonism in hypothalamus (MC3R/MC4R activation) | Peripheral PDE5 inhibition
This comparison does not assign a generated winner or score.
- | Criterion | PT-141 (Bremelanotide) | Sildenafil (PDE5 Inhibitor) | Tadalafil (PDE5 Inhibitor) | Professional Assessment ||—|—|—|—|| Primary Mechanism | Central melanocortin receptor agonism in hypothalamus (MC3R/MC4R activation) | Peripheral PDE5 inhibition → cGMP elevation → nitric oxide-mediated vasodilation | Peripheral PDE5 inhibition with extended half-life (17.5 hours) | PT-141 addresses psychogenic dysfunction at the neurochemical level; PDE5 inhibitors require intact vascular function and fail when the problem is stress-driven arousal suppression || Onset of Action | 30–60 minutes, peak effect 60–90 minutes | 30–60 minutes, requires sexual stimulation to activate | 30–60 minutes, remains active up to 36 hours | PT-141 provides broader effective window without requiring immediate stimulation; PDE5 inhibitors are stimulus-dependent || Efficacy in Psychogenic Dysfunction | 60–70% response rate in subjects with anxiety-driven dysfunction (published trials) | 25–40% response rate